Analysis of the latest market price and purchasing channels of EIKANCE 0.01% Atropine Sulfate Eye Drops

0.01% Atropine Sulfate Eye Drops (EIKANCE) is a low-concentration atropine drug used to control the progression of myopia in children. This drug has attracted widespread attention around the world in recent years, especially in the field of adolescent ophthalmology prevention and control, and has significant application value. However, the original drug has not yet been officially launched in mainland China, and therefore has not been included in the national medical insurance directory. Patients who need the drug can only obtain it through overseas channels, the price is relatively high, and the access methods are relatively limited.

In overseas markets, the original brand of atropine sulfate eye drops has been sold in some European, American and Asian countries. The common specification is 0.01% concentration, and each box contains 0.3ml Since the import of drugs involves exchange rate changes, transportation costs and intermediary links, their market prices may fluctuate between different regions and purchasing channels. They are generally purchased through designated pharmacies or cross-border medical platforms in Hong Kong, Australia, Singapore and other regions.

In addition to the original drug, there are also generic versions of atropine sulfate eye drops on the market in some countries. The ingredients of the drug are basically the same as the original drug. Take the generic drugs produced in India as an example. The common specifications are 0.01% w/v*5ml. Each bottle may be sold for tens of yuan, which is very cost-effective. Such generic drugs are usually obtained through overseas purchasing agents, cross-border e-commerce platforms or qualified international drug intermediaries, but patients should pay attention to the formality of product sources and drug quality when choosing.

Overall, 0.01%The domestic accessibility of atropine sulfate eye drops is still low. However, as the public’s awareness of myopia prevention and control among teenagers increases, the market demand for this type of drug continues to rise. In the future, if the original drug is officially approved for marketing in China and included in medical insurance, the price is expected to be more affordable. At the same time, parents should mainly rely on doctors’ advice when choosing medicines, avoid blindly following the trend and ensure the safety and standardization of drug use.

Reference materials:https://www.medsafe.govt.nz/profs/datasheet/e/EikanceEyeDrops.pdf